May 24, 2019
ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) issued a statement in response to the proposed “Connecticut Option,” which imposes an assessment on the first sale of prescription opioids.
“As an industry, HDA supports efforts to address affordability and reduce healthcare costs. However, the proposed tax on prescription medicines in Connecticut does not align with the state’s efforts to reduce costs for patients. In fact, this misguided approach could ultimately lead to increased costs for patients and healthcare providers, as well as limit access to legitimate medicines. At a time when all states are trying to lower costs for healthcare and expand access, this proposal would do exactly the opposite.”
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.